Pathology, Therapy and Prognosis of Papillary Renal Carcinoma

References

• Ljungberg B , CampbellSC, ChoiHYet al. The epidemiology of renal cell carcinoma. Eur. Urol.60(4), 615–621 (2011).
   PubMed Web of Science ®Google Scholar
• GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. http://globocan.iarc.fr
   Google Scholar
• Levi F , FerlayJ, GaleoneCet al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int.101(8), 949–958 (2008).
   PubMed Web of Science ®Google Scholar
• John N , EbleMD, Guido SauterMDet al. World Health Organization Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, France (2004).
   Google Scholar
• Morabito RA , TalugC, ZaslauS, KandzariS. Asymptomatic advanced pediatric papillary renal cell carcinoma presenting as a pulmonary embolus. Urology76(1), 153–155 (2010).
   PubMed Web of Science ®Google Scholar
• Hagenkord JM , GatalicaZ, JonaschE, MonzonFA. Clinical genomics of renal epithelial tumors. Cancer Genet.204(6), 285–297 (2011).
   PubMed Web of Science ®Google Scholar
• Srigley JR , DelahuntB, EbleJNet al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am. J. Surg. Pathol.37(10), 1469–1489 (2013).
   PubMed Web of Science ®Google Scholar
• Nouh MA , KurodaN, YamashitaMet al. Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int.105(5), 620–627 (2010).
   PubMed Web of Science ®Google Scholar
• Peces R , Martinez-AraJ, MiguelJLet al. Renal cell carcinoma co-existent with other renal disease: clinico–pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol. Dial. Transplant.19(11), 2789–2796 (2004).
   PubMed Web of Science ®Google Scholar
• Perlman EJ . Pediatric renal cell carcinoma. Surg. Pathol. Clin.3(3), 641–651 (2010).
   PubMedGoogle Scholar
• Vikram R , NgCS, TamboliPet al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics29(3), 741–754; discussion755–747 (2009).
   PubMed Web of Science ®Google Scholar
• Purdue MP , MooreLE, MerinoMJet al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case–control studies. Int. J. Cancer132(11), 2640–2647 (2013).
   PubMed Web of Science ®Google Scholar
• Weikert S , BoeingH, PischonTet al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am. J. Epidemiol.167(4), 438–446 (2008).
   PubMed Web of Science ®Google Scholar
• Bhatnagar R , AlexievBA. Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. Int. J. Surg. Pathol.20(1), 19–28 (2012).
   PubMed Web of Science ®Google Scholar
• Dellavalle CT , DanielCR, Aschebrook-KilfoyBet al. Dietary intake of nitrate and nitrite and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study. Br. J. Cancer108(1), 205–212 (2013).
   PubMed Web of Science ®Google Scholar
• Daniel CR , CrossAJ, GraubardBIet al. Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma. Am. J. Clin. Nutr.95(1), 155–162 (2012).
   PubMed Web of Science ®Google Scholar
• Kuroda N , ToiM, HiroiM, EnzanH. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol. Histopathol.18(2), 487–494 (2003).
   PubMed Web of Science ®Google Scholar
• Barrisford GW , SingerEA, RosnerIL, LinehanWM, BratslavskyG. Familial renal cancer: molecular genetics and surgical management. Int. J. Surg. Oncol.2011, 658767 (2011).
   PubMedGoogle Scholar
• Choyke PL , GlennGM, WaltherMM, ZbarB, LinehanWM. Hereditary renal cancers. Radiology226(1), 33–46 (2003).
   PubMed Web of Science ®Google Scholar
• Czene K , HemminkiK. Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden. J. Urol.169(4), 1271–1275 (2003).
   PubMed Web of Science ®Google Scholar
• Choyke PL . Imaging of hereditary renal cancer. Radiol. Clin. North Am.41(5), 1037–1051 (2003).
   PubMed Web of Science ®Google Scholar
• Wadt KA , GerdesAM, HansenTV, ToftBG, Friis-HansenL, AndersenMK. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Fam. Cancer11(3), 535–537 (2012).
   PubMed Web of Science ®Google Scholar
• Alam NA , RowanAJ, WorthamNCet al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet.12(11), 1241–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Lin ZH , HanEM, LeeESet al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod. Pathol.17(6), 611–616 (2004).
   PubMed Web of Science ®Google Scholar
• Verine J , PluvinageA, BousquetGet al. Hereditary renal cancer syndromes: an update of a systematic review. Eur. Urol.58(5), 701–710 (2010).
   PubMed Web of Science ®Google Scholar
• Lehtonen HJ . Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam. Cancer10(2), 397–411 (2011).
   PubMed Web of Science ®Google Scholar
• Van Spaendonck-Zwarts KY , BadeloeS, OostingSFet al. Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance. Fam. Cancer11(1), 123–129 (2012).
   PubMed Web of Science ®Google Scholar
• Azeem K , KollarovaH, HorakovaD, MagnuskovaS, JanoutV. Genetic syndromes associated with renal cell carcinoma: a review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.155(3), 231–238 (2011).
   PubMed Web of Science ®Google Scholar
• Kiuru M , KujalaM, AittomakiK. Inherited forms of renal cell carcinoma. Scand. J. Surg.93(2), 103–111 (2004).
   PubMedGoogle Scholar
• Mester JL , ZhouM, PrescottN, EngC. Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology79(5), 1187.e1–7 (2012).
   PubMed Web of Science ®Google Scholar
• Linehan WM , PintoPA, BratslavskyGet al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer115(10 Suppl.), 2252–2261 (2009).
   PubMed Web of Science ®Google Scholar
• Lubensky IA , SchmidtL, ZhuangZet al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am. J. Pathol.155(2), 517–526 (1999).
   PubMed Web of Science ®Google Scholar
• Malinoc A , SullivanM, WiechTet al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr. Relat. Cancer19(3), 283–290 (2012).
   PubMed Web of Science ®Google Scholar
• Hora M , HesO, KleckaJet al. Rupture of papillary renal cell carcinoma. Scand, J. Urol. Nephrol.38(6), 481–484 (2004).
   PubMed Web of Science ®Google Scholar
• Brunelli M , EbleJN, ZhangS, MartignoniG, ChengL. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod. Pathol.16(10), 1053–1059 (2003).
   PubMed Web of Science ®Google Scholar
• Mclaughlin JK , LipworthL. Epidemiologic aspects of renal cell cancer. Semin. Oncol.27(2), 115–123 (2000).
   PubMed Web of Science ®Google Scholar
• Mancilla-Jimenez R , StanleyRJ, BlathRA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer38(6), 2469–2480 (1976).
   PubMed Web of Science ®Google Scholar
• Kovacs G . Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am. J. Pathol.134(1), 27–34 (1989).
   PubMed Web of Science ®Google Scholar
• Yang XJ , TanMH, KimHLet al. A molecular classification of papillary renal cell carcinoma. Cancer Res.65(13), 5628–5637 (2005).
   PubMed Web of Science ®Google Scholar
• Pignot G , ElieC, ConquySet al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology69(2), 230–235 (2007).
   PubMed Web of Science ®Google Scholar
• Gobbo S , EbleJN, MaclennanGTet al. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am. J. Surg. Pathol.32(12), 1780–1786 (2008).
   PubMed Web of Science ®Google Scholar
• Yu W , ZhangW, JiangYet al. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information. Acta Histochem.115(5), 452–459 (2013).
   PubMed Web of Science ®Google Scholar
• Truong LD , ShenSS. Immunohistochemical diagnosis of renal neoplasms. Arch. Pathol. Lab. Med.135(1), 92–109 (2011).
   PubMed Web of Science ®Google Scholar
• Bing Z , LalP, LuS, ZioberA, TomaszewskiJE. Role of carbonic anhydrase IX, alpha-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study. Ann. Diagn. Pathol.17(1), 58–62 (2013).
   PubMed Web of Science ®Google Scholar
• Kuroda N , KanomataN, YamaguchiTet al. Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma. Med. Mol. Morphol.44(2), 111–115 (2011).
   PubMed Web of Science ®Google Scholar
• Hornsby CD , CohenC, AminMBet al. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling. Arch. Pathol. Lab. Med.131(10), 1541–1546 (2007).
   PubMed Web of Science ®Google Scholar
• Fritzsche FR , OelrichB, JohannsenMet al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin. Cancer Res.14(21), 7035–7042 (2008).
   PubMed Web of Science ®Google Scholar
• Hagemann T , GunawanB, SchulzM, FuzesiL, BinderC. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur. J. Cancer37(15), 1839–1846 (2001).
   PubMed Web of Science ®Google Scholar
• Bremmer F , HemmerleinB, StraussAet al. N-cadherin expression in malignant germ cell tumours of the testis. BMC Clin. Pathol.12, 19 (2012).
   PubMedGoogle Scholar
• Chute DJ , KongCS, StelowEB. Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology. Diagn. Cytopathol.39(2), 118–123 (2011).
   PubMed Web of Science ®Google Scholar
• Duzcan F , DuzcanSE, SenSet al. Expression and amplification of topoisomerase-2alpha in type 1 and type 2 papillary renal cell carcinomas and its correlation with HER2/neu amplification. Pathol. Oncol. Res.17(3), 697–703 (2011).
   PubMed Web of Science ®Google Scholar
• Roos FC , EvansAJ, BrennerWet al. Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma. Am. J. Pathol.178(2), 853–860 (2011).
   PubMed Web of Science ®Google Scholar
• Furge KA , ChenJ, KoemanJet al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res.67(7), 3171–3176 (2007).
   PubMed Web of Science ®Google Scholar
• Morrissey JJ , KharaschED. The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma. J. Urol.189(5), 1913–1920 (2013).
   PubMed Web of Science ®Google Scholar
• Matusan K , DordevicG, MozeticV, LucinK. Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol. Oncol. Res.11(2), 108–113 (2005).
   PubMed Web of Science ®Google Scholar
• Leroy X , ZiniL, LeteurtreEet al. Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod. Pathol.15(11), 1126–1130 (2002).
   PubMed Web of Science ®Google Scholar
• Langner C , RatschekM, RehakP, SchipsL, ZigeunerR. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod. Pathol.17(2), 180–188 (2004).
   PubMed Web of Science ®Google Scholar
• Li G , CuilleronM, Gentil-PerretAet al. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. Clin. Cancer Res.9(17), 6441–6446 (2003).
   PubMed Web of Science ®Google Scholar
• Langner C , WegscheiderBJ, RatschekM, SchipsL, ZigeunerR. Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Arch.444(2), 127–134 (2004).
   PubMed Web of Science ®Google Scholar
• Delahunt B , EbleJN, MccredieMR, BethwaitePB, StewartJH, BilousAM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol.32(6), 590–595 (2001).
   PubMed Web of Science ®Google Scholar
• Lim JC , WojcikEM. Fine-needle aspiration cytology of papillary renal cell carcinoma: the association with concomitant secondary malignancies. Diagn. Cytopathol.34(12), 797–800 (2006).
   PubMed Web of Science ®Google Scholar
• del Vecchio MT , LazziS, BruniA, MangiavacchiP, CeveniniG, LuziP. DNA ploidy pattern in papillary renal cell carcinoma. Correlation with clinicopathological parameters and survival. Pathol. Res. Pract.194(5), 325–333 (1998).
   PubMed Web of Science ®Google Scholar
• Amo-Takyi BK , MittermayerC, GuntherK, HandtS. Interphase cytogenetics of multicentric renal cell tumours confirm associations of specific aberrations with defined cytomorphologies. Br. J. Cancer82(8), 1407–1414 (2000).
   PubMed Web of Science ®Google Scholar
• Nagy A , BalintI, KovacsG. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int. J. Cancer106(6), 980–981 (2003).
   PubMed Web of Science ®Google Scholar
• Shridhar V , WangL, RosatiRet al. Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas. Oncogene14(11), 1269–1277 (1997).
   PubMed Web of Science ®Google Scholar
• Henke RP , ErbersdoblerA. Numerical chromosomal aberrations in papillary renal cortical tumors: relationship with histopathologic features. Virchows Arch.440(6), 604–609 (2002).
   PubMed Web of Science ®Google Scholar
• Glukhova L , AngevinE, LavialleCet al. Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet. Cytogenet.130(2), 105–110 (2001).
   PubMedGoogle Scholar
• Simon-Kayser B , ScoulC, RenaudinKet al. Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal cell carcinoma. Genes, Chromosomes Cancer43(1), 83–94 (2005).
   PubMed Web of Science ®Google Scholar
• Thrash-Bingham CA , SalazarH, FreedJJ, GreenbergRE, TartofKD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res.55(24), 6189–6195 (1995).
   PubMed Web of Science ®Google Scholar
• Gurel S , NarraV, ElsayesKM, SiegelCL, ChenZE, BrownJJ. Subtypes of renal cell carcinoma: MRI and pathological features. Diagn. Interv. Radiol.19(4), 304–311 (2013).
   PubMed Web of Science ®Google Scholar
• Clark J , LuYJ, SidharSKet al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene15(18), 2233–2239 (1997).
   PubMed Web of Science ®Google Scholar
• Morrissey C , MartinezA, ZatykaMet al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res.61(19), 7277–7281 (2001).
   PubMed Web of Science ®Google Scholar
• Mathur M , DasS, SamuelsHH. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration. Oncogene22(32), 5031–5044 (2003).
   PubMed Web of Science ®Google Scholar
• Soller MJ , KullendorffCM, BekassyAN, AlumetsJ, MertensF. Cytogenetic findings in pediatric renal cell carcinoma. Cancer Genet. Cytogenet.173(1), 75–80 (2007).
   PubMedGoogle Scholar
• Weterman MA , Van GroningenJJ, Den HartogA, Geurts Van KesselA. Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes. Oncogene20(12), 1414–1424 (2001).
   PubMed Web of Science ®Google Scholar
• Gunawan B , Von HeydebreckA, FritschTet al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res.63(19), 6200–6205 (2003).
   PubMed Web of Science ®Google Scholar
• Jiang F , RichterJ, SchramlPet al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol.153(5), 1467–1473 (1998).
   PubMed Web of Science ®Google Scholar
• Velickovic M , DelahuntB, StorkelS, GrebemSK. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res.61(12), 4815–4819 (2001).
   PubMed Web of Science ®Google Scholar
• Sanders ME , MickR, TomaszewskiJE, BarrFG. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am. J. Pathol.161(3), 997–1005 (2002).
   PubMed Web of Science ®Google Scholar
• Antonelli A , TardanicoR, BalzariniPet al. Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet. Cytogenet.199(2), 128–133 (2010).
   PubMedGoogle Scholar
• Al-Saleem T , BalsaraBR, LiuZet al. Renal oncocytoma with loss of chromosomes Y and 1 evolving to papillary carcinoma in connection with gain of chromosome 7. Coincidence or progression? Cancer Genet. Cytogenet. 163(1), 81–85 (2005).
   PubMedGoogle Scholar
• Ramphal R , PappoA, ZielenskaM, GrantR, NganBY. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am. J. Clin. Pathol.126(3), 349–364 (2006).
   PubMed Web of Science ®Google Scholar
• Schraml P , MullerD, BednarRet al. Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J. Pathol.190(4), 457–461 (2000).
   PubMed Web of Science ®Google Scholar
• Morris MR , MaherER. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med.2(9), 59 (2010).
   PubMedGoogle Scholar
• Awakura Y , NakamuraE, ItoN, KamotoT, OgawaO. Methylation-associated silencing of TU3A in human cancers. Int. J. Oncol.33(4), 893–899 (2008).
   PubMed Web of Science ®Google Scholar
• Ooi A , DykemaK, AnsariAet al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res.73(7), 2044–2051 (2013).
   PubMed Web of Science ®Google Scholar
• Escudier B , EisenT, PortaCet al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.23(Suppl. 7), vii65–vii71 (2012).
   PubMed Web of Science ®Google Scholar
• Pal SK , NelsonRA, VogelzangN. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS ONE8(5), e63341 (2013).
   PubMed Web of Science ®Google Scholar
• Tuthill M , BarodR, PyleLet al. A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib. BMJ. Case Rep.2009, bcr08.2008.0732 (2009).
   PubMedGoogle Scholar
• Tazi El M , EssadiI, TaziMF, AhellalY, M’rabtiH, ErrihaniH. Advanced treatments in non-clear renal cell carcinoma. Urol. J.8(1), 1–11 (2011).
   PubMed Web of Science ®Google Scholar
• Ljungberg B , CowanNC, HanburyDCet al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol.58(3), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , PlantadeA, ElsonPet al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26(1), 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Dutcher JP , De SouzaP, McdermottDet al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol.26(2), 202–209 (2009).
   PubMed Web of Science ®Google Scholar
• Yang S , De SouzaP, AlemaoE, PurvisJ. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br. J. Cancer102(10), 1456–1460 (2010).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , DutcherJ. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann. Oncol.24(7), 1730–1740 (2013).
   PubMed Web of Science ®Google Scholar
• Koh Y , LimHY, AhnJHet al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann. Oncol.24(4), 1026–1031 (2013).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , VaishampayanU, RosenbergJEet al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol.31(2), 181–186 (2013).
   PubMed Web of Science ®Google Scholar
• Escudier B , BellmuntJ, NegrierSet al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , AgarwalN, BeardCet al. NCCN clinical practice guidelines in oncology: kidney cancer. J. Natl Compr. Canc. Netw.7(6), 618–630 (2009).
   PubMedGoogle Scholar
• Ronnen EA , KondaguntaGV, IshillNet al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer107(11), 2617–2621 (2006).
   PubMed Web of Science ®Google Scholar
• Lim R , TanPH, ChengCet al. A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases J.2, 7769 (2009).
   PubMedGoogle Scholar
• Ku JH , MoonKC, KwakC, KimHH, LeeSE. Is there a role of the histologic subtypes of papillary renal cell carcinoma as a prognostic factor?Jpn J. Clin. Oncol.39(10), 664–670 (2009).
   PubMed Web of Science ®Google Scholar
• Lohse CM , BluteML, ZinckeH, WeaverAL, ChevilleJC. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am. J. Clin. Pathol.118(6), 877–886 (2002).
   PubMed Web of Science ®Google Scholar
• Mitsufuji T , FujimitsuR, IdaMet al. Papillary renal cell carcinoma with extensive paraaortic nodal metastasis mimicking malignant lymphoma. Magn. Reson. Med. Sci.10(3), 201–204 (2011).
   PubMed Web of Science ®Google Scholar
• Pichler M , HuttererGC, ChromeckiTFet al. Histologic tumor necrosis is an independent prognostic indicator for clear cell and papillary renal cell carcinoma. Am. J. Clin. Pathol.137(2), 283–289 (2012).
   PubMed Web of Science ®Google Scholar
• Waalkes S , AtschekzeiF, KramerMWet al. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer10, 503 (2010).
   PubMed Web of Science ®Google Scholar
• Uhlman DL , NguyenP, ManivelJCet al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer Res.1(8), 913–920 (1995).
   PubMed Web of Science ®Google Scholar
• Amare Kadam PS , VargheseC, BhardeSHet al. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. Cancer Genet. Cytogenet.125(2), 139–146 (2001).
   PubMedGoogle Scholar
• Sengupta S , LohseCM, ChevilleJCet al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer106(2), 304–312 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang Z , LohseCM, ChuPGet al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer112(12), 2676–2682 (2008).
   PubMed Web of Science ®Google Scholar
• Pichler M , HuttererGC, ChromeckiTFet al. Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma. Histopathology62(2), 237–246 (2013).
   PubMed Web of Science ®Google Scholar
• Steffens S , JanssenM, RoosFCet al. Incidence and long-term prognosis of papillary compared with clear cell renal cell carcinoma – a multicentre study. Eur. J. Cancer48(15), 2347–2352 (2012).
   PubMed Web of Science ®Google Scholar
• Patard JJ , LerayE, Rioux-LeclercqNet al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol.23(12), 2763–2771 (2005).
   PubMed Web of Science ®Google Scholar